Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Alexander

Showing results (1101-1110 of 1,212) with videos related to

Pageof 122
Sort By:
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
JAMA Cardiology|May 25, 2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS TrialM Cecilia Bahit, Amit N Vora, Zhuokai Li, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 27, 2011
Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials NetworkPeter K Smith, Robert E Michler, Y Joseph Woo, et al.
American Heart Journal|May 20, 2026
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practicePishoy Gouda, Josephine Harrington, Kelly Arps, et al.
JAMA|November 13, 2018
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical TrialJulio Rosenstock, Vlado Perkovic, Odd Erik Johansen, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
Biochemical and Biophysical Research Communications|October 13, 2007
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell deathAndriani Athanasiou, Anna B Clarke, Amy E Turner, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
British Journal of Pharmacology|June 8, 2022
Planning experiments: Updated guidance on experimental design and analysis and their reporting IIIMichael J Curtis, Stephen P H Alexander, Giuseppe Cirino, et al.
Pageof 122

Showing results (1101-1110 of 1,212) with videos related to

Sort By:
Pageof 122
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
JAMA Cardiology|May 25, 2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS TrialM Cecilia Bahit, Amit N Vora, Zhuokai Li, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 27, 2011
Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials NetworkPeter K Smith, Robert E Michler, Y Joseph Woo, et al.
American Heart Journal|May 20, 2026
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practicePishoy Gouda, Josephine Harrington, Kelly Arps, et al.
JAMA|November 13, 2018
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical TrialJulio Rosenstock, Vlado Perkovic, Odd Erik Johansen, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
Biochemical and Biophysical Research Communications|October 13, 2007
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell deathAndriani Athanasiou, Anna B Clarke, Amy E Turner, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
British Journal of Pharmacology|June 8, 2022
Planning experiments: Updated guidance on experimental design and analysis and their reporting IIIMichael J Curtis, Stephen P H Alexander, Giuseppe Cirino, et al.
Pageof 122